v3.25.0.1
Licensing, Acquisitions, and Other Arrangements (Details) - Cerevel Therapeutics - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
5 Months Ended 11 Months Ended 12 Months Ended
Aug. 01, 2024
Dec. 31, 2024
Dec. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition            
Payments to Acquire Businesses, Net of Cash Acquired       $ 17,493 $ 0 $ 255
Goodwill   $ 34,956 $ 34,956 $ 34,956 $ 32,293 $ 32,156
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized     $ 510      
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]   Research and development        
RSUs            
Business Acquisition            
Granted (in shares)   300 300 600    
Pfizer License Agreement            
Business Acquisition            
Aggregate Amount of Commercial Milestones Payable $ 1,600          
Cerevel Therapeutics            
Business Acquisition            
Cash per share received by shareholders (in dollars per share) $ 45.00          
Cash consideration paid $ 8,700          
Payments to Acquire Businesses, Net of Cash Acquired 8,300          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents 361          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities 382          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other 9          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment 25          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets 121          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assumed In Process Research and Development 8,100          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets 31          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt (400)          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable (100)          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt (246)          
Deferred tax liabilities (1,292)          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other (31)          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net 6,960          
Goodwill 1,702          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 8,662          
Aggregate principal amount of debt $ 345          
Stated interest rate (as a percent) 2.50%          
Short-term borrowings $ (400)          
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual   $ (4,900)        
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized   161        
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)   $ 4,500        
Cerevel Therapeutics | Selling, general and administrative            
Business Acquisition            
Business Combination, Acquisition Related Costs       $ 44